PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/740,266

Filing Date: December 18, 2003

Applicant: Christian Auclair et al.

Group Art Unit: 1642

Examiner: Brandon J. Fetterolf

Title: PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS,

PREVENTION OR TREATMENT OF A TUMORAL PATHOLOGY COMPRISING AN AGENT MODULATING THE

POLYMERIZATION STATE OF ACTIN

Attorney Docket: 4384-000067/CO

Director of the United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION</u>

The patents, publications and other information requested to be considered by the Office (except unpublished U.S. patent applications) are listed on Form 1449 attached hereto.

II. COPIES

A. Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) each unpublished U.S. application listed below in Section IV (i.e., including the specification, claims, and any drawing of the application, or that portion of the application which caused it to be listed, including any claims directed to that portion), except for such applications filed on or after June 30, 2003, pursuant to the Waiver of the Copy Requirement in 37 C.F.R. 1.98 (OG Notice dated

	October 19, 2004); and (iv) all other information be listed.	n or that portion which caused it to	
	B. Any patents, publications or other info 1449 or on the copies of PTO-892, but which previously cited by or submitted to the PTO ir which has been relied upon for an earlier filing	n are not enclosed herewith, were n one of the following applications	
	U.S. Serial Number	U.S. Filing Date	
	C. This is a PCT application in the entry of the National Phase in the Unite States. A copy of the International Search Report is attached for the Examiner information. The documents listed on the International Search report are listed on the attached Form 1449 for consideration by the Examiner and for listing of any patent resulting from this application. If the International Search report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g).)		
111.	CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)		
	A. Except as may be indicated below in (B other information are in the English language (•	
	B. A concise explanation of the relevance of information listed that is not in the English lang § 1.98(a)(3)):		
	1. See the attached foreign pate counterpart foreign application:	nt office communication from a	
	2. English translations are provided:		
	3. Other:		
	C. The following additional information consideration.	is provided for the Examiner's	

IV.	CROSS REFERENCE TO RELATED AFFLICATION(S)			
	A. The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does (do) not waive the confidentiality provisions of 35 U.S.C. § 122.			
	Serial No.	Filing Date	Inventor(s)	
V.	THIS IDS IS BEING FILED UNDER			
	A. 37 C.F.R. § 1.9	7(b): (check <u>only</u> one box)		
	than a continu		ate of a national application other on under § 1.53(d) (37 C.F.R. § uired.	
	forth in § 1.49		entry of the national stage as set ation (37 C.F.R. § 1.97(b)(2)). No	
	1.97(b)(3)). NOffice Action under 37 C.F	lo fee or certification is re on the merits has been i .R. § 1.97(c) and see the or, if no certification has	Action on the merits (37 C.F.R. § equired. In the event that a first issued, please consider this IDS e certification under 37 C.F.R. § been made, charge our deposit as required by 37 C.F.R. § 1.17(p)	
			Action after the filing of a request R. § 1.114. No fee or certification	
	B. 🔀 37 C.F.R. § 1.9	7(c): (check <u>only</u> one box)		
	1.113, a Notic		al Office Action under 37 C.F.R. § C.F.R. § 1.311, or an action that	
	1. ⊠ No certif by 37 C.F.R. §	•	the amount of \$180.00 is required	
	2. See the	certification below. No fee	is required.	

	C. 37 C.F.R. § 1.97(d):
	after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.
	1. See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
√I.	CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)
	The undersigned hereby certifies that:
	A. each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. 1.704(d) below in section VII, if applicable; or
	B. no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).
	C. some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.
VII.	STATEMENT UNDER 37 C.F.R. 1.704(d)
	The undersigned hereby states that:
	each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box, if applicable)

- A. A check in the amount of \$180.00 is enclosed for the above-identified fee.
- B. \boxtimes Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-identified fee.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. § 1.16 or § 1.17 to Deposit Account No. 08-0750.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Respectfully submitted,

Dated: August 5, 2008

David L. Suter Reg. No. 30,692

Bv: , ,

Harness, Dickey & Pierce, P.L.C. P.O. Box 828
Bloomfield Hills, Michigan 48303 (248) 641-1600

DLS/kg